NCT03367247

Brief Summary

This research study is evaluating a new intervention, BOLSTER, which was designed to provide more support for patients with gynecologic and gastrointestinal cancers and their caregivers after a hospitalization.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
121

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2018

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 28, 2017

Completed
10 days until next milestone

First Posted

Study publicly available on registry

December 8, 2017

Completed
5 months until next milestone

Study Start

First participant enrolled

April 24, 2018

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
1.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 27, 2023

Completed
19 days until next milestone

Results Posted

Study results publicly available

August 15, 2023

Completed
Last Updated

March 10, 2026

Status Verified

February 1, 2026

Enrollment Period

4.2 years

First QC Date

November 28, 2017

Results QC Date

June 15, 2023

Last Update Submit

February 26, 2026

Conditions

Keywords

Ovarian CancerBowel blockageAscitesSupportive careNursingMobile healthm-HealthTele-healthPalliative CareSymptom managementGastrointestinal CancerGynecologic CancerComplex Care Needs

Outcome Measures

Primary Outcomes (1)

  • Feasibility of the BOLSTER Intervention

    ≥50% consent-to-approach ratio

    1 month

Secondary Outcomes (1)

  • Acceptability of the BOLSTER Intervention

    3 months

Study Arms (2)

Bolster

EXPERIMENTAL

* Bolster provides participants with longitudinal nursing support across care settings, * A smartphone-based symptom management app, * A print and web-based symptom management toolkit, * Advance care planning to ensure that the patient receives care that is congruent with her informed preferences * BOLSTER includes a total of 6 contacts with a study nurse over 4 weeks * Daily contact via a smartphone-based symptom app which queries patients about their symptoms using questions from the PRO-CTCAE, risk-stratifies their symptoms, and provides tailored symptom management advice

Behavioral: BOLSTER

Enhanced Discharge Planning (EDP)

OTHER

* Medication education, * Self-management strategies for symptoms, * Skills training, * A list of red flag symptoms and numbers for who to call

Other: Enhanced Discharge Planning (EDP)

Interventions

BOLSTERBEHAVIORAL

BOLSTER provides patients and caregivers with education and skills training, symptom management, and support across care settings over a four-week period.

Bolster

EDP provides patients and caregivers a single session of education and skills training, symptom management, and support.

Enhanced Discharge Planning (EDP)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (≥18 years old);
  • GYN or GI cancers receiving anti-neoplastic therapy;
  • Hospitalized, recently hospitalized (i.e. within the first 2 visits after a hospitalization), or recent outpatient placement of tube, line, or drain (e.g. PleurX catheter);
  • Plan to receive ongoing care at DFCI;
  • Willingness to be audio taped for the study (for monitoring of study fidelity).
  • Have complex care needs (e.g. an ostomy, ileostomy, a gastric tube, percutaneous nephrostomy tubes, a PleurX catheter, or need for total parenteral nutrition)

You may not qualify if:

  • Unable to read and respond to questions in English;
  • Cognitive impairment;
  • Unable to complete the baseline interview;
  • Plan for immediate hospice referral
  • Adults (≥18 years old);
  • Family member or friend of an eligible patient;
  • Willingness to be audio taped for the study (for monitoring of study fidelity);
  • Willingness to participate in study visits
  • Unable to read and respond to questions in English,
  • Cognitive impairment
  • Unable to complete the baseline interview

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

Location

Related Publications (2)

  • Pozzar RA, Enzinger AC, Poort H, Furey A, Donovan H, Orechia M, Thompson E, Tavormina A, Fenton ATHR, Jaung T, Braun IM, DeMarsh A, Cooley ME, Wright AA. Developing and Field Testing BOLSTER: A Nurse-Led Care Management Intervention to Support Patients and Caregivers following Hospitalization for Gynecologic Cancer-Associated Peritoneal Carcinomatosis. J Palliat Med. 2022 Sep;25(9):1367-1375. doi: 10.1089/jpm.2021.0618. Epub 2022 Mar 17.

    PMID: 35297744BACKGROUND
  • Pozzar RA, Enzinger AC, Howard C, Tavormina A, Matulonis UA, Campos S, Liu JF, Horowitz N, Konstantinopoulos PA, Krasner C, Wall JA, Sciacca K, Meyer LA, Lindvall C, Wright AA. Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial. Gynecol Oncol. 2024 Sep;188:1-7. doi: 10.1016/j.ygyno.2024.06.001. Epub 2024 Jun 7.

MeSH Terms

Conditions

Gastrointestinal NeoplasmsOvarian NeoplasmsAscites

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesEndocrine Gland NeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal DisordersPathologic ProcessesPathological Conditions, Signs and Symptoms

Results Point of Contact

Title
Dr. Alexi Wright
Organization
Dana-Farber Cancer Institute

Study Officials

  • Alexi A Wright, MD, MPH

    Dana-Farber Cancer Institute

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Clinical research assistant blinded to randomized study arms; will conduct structured interview at baseline, prior to randomization, and 4 weeks post randomization +/- 2 weeks.
Purpose
SUPPORTIVE CARE
Intervention Model
SINGLE GROUP
Model Details: Phase I: Single-arm study with up to 20 ovarian cancer patients and their informal caregivers run-in. Phase II: Two-arm pilot RCT with 60 gynecologic or gastrointestinal cancer patients and their informal caregivers (30 dyads in each arm).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

November 28, 2017

First Posted

December 8, 2017

Study Start

April 24, 2018

Primary Completion

June 30, 2022

Study Completion

July 27, 2023

Last Updated

March 10, 2026

Results First Posted

August 15, 2023

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will not share

Locations